| Company/Division name | Audentes Therapeutics |
| Parent company | Astellas Co |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 209 |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2021 |
| Capital investment ($): | 109 |
| City reshored to: | Sanford |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | genetic medicine |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Higher productivity, Infrastructure, Lead time/Time to market, Lean/other business process improvement techniques, Skilled workforce availability/training |
| Government Incentive dollar amount: | 3.7 |
